![[dr. bob]](/dr-bob-sm.gif)
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.orgShown: posts 1 to 5 of 5. This is the beginning of the thread.
Posted by Ant-Rock on October 1, 2008, at 21:03:05
I thought this was pretty interesting...
Rexahn wins approval to initiate Phase II study of depression drug
US-based biopharmaceutical company Rexahn Pharmaceuticals has received the FDA approval to begin Phase II trials for Serdaxin, for the treatment of major depressive disorders.The Serdaxin Phase II trial is a randomized, double-blind, placebo-controlled parallel study for the treatment of major depressive disorders. It is a multi-center trial with preliminary data in humans expected in the second half of 2009.
According to the company, Serdaxin is being developed as an orally administered, extended release tablet for the treatment of depression and anxiety. It is a dual enhancer of serotonin and dopamine neurotransmitters. In preclinical studies, Serdaxin was shown to significantly improve an individual's negative mood state and the loss of positive mood state, with the onset of action taking less than two days.
This trial represents the third Phase II study currently in progress at Rexahn Pharmaceuticals. The company's cancer compound, Archexin, and its drug for treating erectile dysfunction, Zoraxel, are already in Phase II trials at multiple locations in the US.
Chang Ahn, CEO of Rexahn Pharmaceuticals, said: "We are very excited to reach this milestone with Serdaxin, which has the potential to become a new market leader for depression, with faster onset of action and broader therapeutic coverage than the present standard of care. Serdaxin also has an excellent safety profile in humans without the negative side effects of the current available treatment, which could increase patient compliance."
Source: Datamonitor
*Also on this site, Agomelatine was mentioned as being marketed for mild to moderate depression, or as an adjuct to other meds for MDD.
Anthony
Posted by desolationrower on October 1, 2008, at 21:19:55
In reply to Interesting Stuff...New Novel AD's, posted by Ant-Rock on October 1, 2008, at 21:03:05
I am pretty sick of hearing about new antidepressants that are monoamine reuptake inhibitors.
I wonder if agomelatine will end up being used as much for insomnia as for depression.
-d/r
Posted by clipper40 on October 2, 2008, at 0:46:55
In reply to Interesting Stuff...New Novel AD's, posted by Ant-Rock on October 1, 2008, at 21:03:05
Does sound interesting. Thanks for posting. Good to know that there may be some other choices on the horizon - just wish they would be available sooner.
Posted by Ant-Rock on October 2, 2008, at 18:48:44
In reply to Re: Interesting Stuff...New Novel AD's, posted by desolationrower on October 1, 2008, at 21:19:55
> I am pretty sick of hearing about new antidepressants that are monoamine reuptake inhibitors.
> -d/rI totally agree d/r.
At least this one seems to have a strong dopamine component.
Anthony
Posted by Bob on October 2, 2008, at 23:48:50
In reply to Re: Interesting Stuff...New Novel AD's, posted by desolationrower on October 1, 2008, at 21:19:55
> I am pretty sick of hearing about new antidepressants that are monoamine reuptake inhibitors.
>
> I wonder if agomelatine will end up being used as much for insomnia as for depression.
>
> -d/r
There isn't much out there in terms of effective AD's if you exclude monamine action. They've been trying, but it just isn't happening as far as I can see.
This is the end of the thread.
Psycho-Babble Medication | Extras | FAQ
Dr. Bob is Robert Hsiung, MD,
bob@dr-bob.org
Script revised: February 4, 2008
URL: http://www.dr-bob.org/cgi-bin/pb/mget.pl
Copyright 2006-17 Robert Hsiung.
Owned and operated by Dr. Bob LLC and not the University of Chicago.